Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations
Marc Souris,
Léon Tshilolo,
Daniel Parzy,
Line Lobaloba Ingoba,
Francine Ntoumi,
Rachel Kamgaing,
Moussa Ndour,
Destin Mbongi,
Balthazar Phoba,
Marie-Anasthasie Tshilolo,
René Mbungu,
Martin Samuel Sosso,
Nadine Fainguem,
Tandakha Ndiaye Dieye,
Massamba Sylla,
Pierre Morand,
Jean-Paul Gonzalez
Affiliations
Marc Souris
UMR Unité des Virus Émergents (UVE Aix-Marseille Univ-IRD 190-Inserm 1207), 13005 Marseille, France
Léon Tshilolo
Centre Hospitalier Mère-Enfant Monkole, Kinshasa, Democratic Republic of the Congo
Daniel Parzy
Defideva/Altadeva—Biological Lab (Inpack), Luminy Biotech, 13009 Marseille, France
Line Lobaloba Ingoba
Fondation Congolaise pour la Recherche Médicale and Faculté des Sciences et Techniques, Brazaville, Democratic Republic of the Congo
Francine Ntoumi
Fondation Congolaise pour la Recherche Médicale and Faculté des Sciences et Techniques, Brazaville, Democratic Republic of the Congo
Rachel Kamgaing
Centre International de Référence Chantal Biya (CIRCB), Yaoundé, Cameroon
Moussa Ndour
Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Plateforme d’Immunologie, Dakar 10200, Senegal
Destin Mbongi
Centre de Formation et d’Appui Sanitaire (CEFA), Mont-Ngafula, Kinshasa BP 817, Democratic Republic of the Congo
Balthazar Phoba
Centre de Formation et d’Appui Sanitaire (CEFA), Mont-Ngafula, Kinshasa BP 817, Democratic Republic of the Congo
Marie-Anasthasie Tshilolo
Centre de Formation et d’Appui Sanitaire (CEFA), Mont-Ngafula, Kinshasa BP 817, Democratic Republic of the Congo
René Mbungu
Centre de Formation et d’Appui Sanitaire (CEFA), Mont-Ngafula, Kinshasa BP 817, Democratic Republic of the Congo
Martin Samuel Sosso
Centre International de Référence Chantal Biya (CIRCB), Yaoundé, Cameroon
Nadine Fainguem
Centre International de Référence Chantal Biya (CIRCB), Yaoundé, Cameroon
Tandakha Ndiaye Dieye
Institut de Recherche en Santé, de Surveillance Epidémiologique et de Formation (IRESSEF), Plateforme d’Immunologie, Dakar 10200, Senegal
Massamba Sylla
Laboratory Vecteurs & Parasites, Department of Livestock Sciences and Techniques, University El Hadji Ibrahima NIASSE, Kaffrine Campus, Kaffrine 24600, Senegal
Pierre Morand
UMI SOURCE (IRD-UVSQ/Paris-Saclay), 78280 Guyancourt, France
Jean-Paul Gonzalez
Department of Microbiology & Immunology, School of Medicine, Georgetown University, Washington, DC 20057, USA
For more than two years after the emergence of COVID-19 (Coronavirus Disease-2019), significant regional differences in morbidity persist. These differences clearly show lower incidence rates in several regions of the African and Asian continents. The work reported here aimed to test the hypothesis of a pre-pandemic natural immunity acquired by some human populations in central and western Africa, which would, therefore, pose the hypothesis of an original antigenic sin with a virus antigenically close to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). To identify such pre-existing immunity, sera samples collected before the emergence of COVID-19 were tested to detect the presence of IgG reacting antibodies against SARS-CoV-2 proteins of major significance. Sera samples from French blood donors collected before the pandemic served as a control. The results showed a statistically significant difference of antibodies prevalence between the collected samples in Africa and the control samples collected in France. Given the novelty of our results, our next step consists in highlighting neutralizing antibodies to evaluate their potential for pre-pandemic protective acquired immunity against SARS-CoV-2. In conclusion, our results suggest that, in the investigated African sub-regions, the tested populations could have been potentially and partially pre-exposed, before the COVID-19 pandemic, to the antigens of a yet non-identified Coronaviruses.